Literature DB >> 22580099

MicroRNAs in pathogenesis, diagnosis, and treatment of gastroesophageal cancers.

Jee Hoon Song1, Stephen J Meltzer.   

Abstract

The incidence of gastroesophageal cancers is increasing each year, but despite much research, their molecular mechanisms are incompletely understood. microRNAs (miRNAs) are noncoding RNAs that have been associated with gastroesophageal carcinogenesis. We review the involvement of miRNAs in gastric and esophageal cancers and their mechanisms of regulation, effects on gene expression, and biological functions. Many miRNAs are dysregulated in gastroesophageal cancer cells via alterations in transcription, epigenetic features, or copy number of the genes that encode them. Each type of gastroesophageal tumor has a unique gene expression profile. miRNAs contribute to gastroesophageal carcinogenesis by altering expression of oncogenes and tumor suppressors to affect cell proliferation, apoptosis, and motility and invasion. A number of miRNAs, including circulating miRNAs, have been associated with tumor type or stage, or patient survival, and might be developed as diagnostic or prognostic markers. Greater understanding of the roles of miRNAs in gastroesophageal carcinogenesis could provide insights into the mechanisms of tumor development and identify therapeutic targets.
Copyright © 2012 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22580099     DOI: 10.1053/j.gastro.2012.05.003

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  84 in total

Review 1.  The role of microRNA in esophageal squamous cell carcinoma.

Authors:  Kazuto Harada; Yoshifumi Baba; Takatsugu Ishimoto; Hironobu Shigaki; Keisuke Kosumi; Naoya Yoshida; Masayuki Watanabe; Hideo Baba
Journal:  J Gastroenterol       Date:  2016-01-21       Impact factor: 7.527

Review 2.  Barrett's Esophagus: A Comprehensive and Contemporary Review for Pathologists.

Authors:  Bita V Naini; Rhonda F Souza; Robert D Odze
Journal:  Am J Surg Pathol       Date:  2016-05       Impact factor: 6.394

3.  MicroRNA 520d-3p inhibits gastric cancer cell proliferation, migration, and invasion by downregulating EphA2 expression.

Authors:  Ruixin Li; Weijie Yuan; Wenjuan Mei; Keda Yang; Zihua Chen
Journal:  Mol Cell Biochem       Date:  2014-07-26       Impact factor: 3.396

Review 4.  The clinical value of ncRNAs in gastric cancer: a systematic review and meta-analyses.

Authors:  Xiaoyun Ding; Xiangxiang Wan; Haizhong Jiang; Haojun Song; Ying Fang; Shengcan Chen; Peifei Li; Junming Guo
Journal:  Tumour Biol       Date:  2015-06

5.  MicroRNA-429 inhibits gastric cancer migration and invasion through the downregulation of specificity protein 1.

Authors:  Jingbin Ni; Yisha Yang; Di Liu; Hui Sun; Shimao Jin; Jingying Li
Journal:  Oncol Lett       Date:  2017-03-17       Impact factor: 2.967

6.  Circulating plasma microRNAs in the detection of esophageal squamous cell carcinoma.

Authors:  Lu Zhang; Bing Dong; Pengfei Ren; Hua Ye; Jianxiang Shi; Jiejie Qin; Kaijuan Wang; Peng Wang; Jianying Zhang
Journal:  Oncol Lett       Date:  2018-06-20       Impact factor: 2.967

7.  MiR-101 inhibits cell growth and tumorigenesis of Helicobacter pylori related gastric cancer by repression of SOCS2.

Authors:  Xiaoying Zhou; Yang Xia; Lin Li; Guoxin Zhang
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

8.  Diagnostic and Management Implications of Basic Science Advances in Barrett's Esophagus.

Authors:  Meghan Jankowski; Sachin Wani
Journal:  Curr Treat Options Gastroenterol       Date:  2015-03

Review 9.  The role of microRNAs in cancers of the upper gastrointestinal tract.

Authors:  Shumei Song; Jaffer A Ajani
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-11-20       Impact factor: 46.802

10.  miR-30 decreases multidrug resistance in human gastric cancer cells by modulating cell autophagy.

Authors:  Xinming Du; Bing Liu; Xuerong Luan; Qing Cui; Leping Li
Journal:  Exp Ther Med       Date:  2017-10-23       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.